why is there a semaglutide shortage ends as FDA sets deadline for compounders FDA declares semaglutide (Ozempic/Wegovy) shortage

By month 4, GI side effects fade into background noise for 85%+ of patients, leaving appetite suppression as the primary ongoing effect, which is the desired therapeutic response

Weigh the benefits and risks of off-label Ozempic use with your doctor

N Engl J Med 384:9891002 Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes

(2024) A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

The dose escalation approach used in research settings typically follows a structured stepwise pattern: Starting dose: A low dose (e.g., 12 mg once weekly) for the initial weeks Intermediate doses: Gradual increases at protocol-specified intervals Maintenance dose: A target dose determined by tolerability and clinical response It is important to note that, as retatrutide is not yet approved for clinical use in the UK, there is currently no officially recommended dosing regimen for patients outside of clinical trial settings

This article is part of the Topical Collection on Metabolism Rights and permissions About this article Cite this article Tak, Y.J., Lee, S.Y